Optimal adjuvant chemotherapy in breast cancer: selection of agents

被引：3
作者：
Esposito, Angela [1 ]
Criscitiello, Carmen [1 ]
Sale, Emanuela Omodeo [2 ]
Curigliano, Giuseppe [1 ]
机构：
[1] Ist Europeo Oncol, Div Early Drug Dev Innovat Therapies, I-20133 Milan, Italy
[2] Ist Europeo Oncol, Div Pharm, I-20133 Milan, Italy
来源：
EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2014年 / 7卷 / 05期
关键词：
breast cancer; chemotherapy; predictive factor; subtype; TOPOISOMERASE-II-ALPHA; GENE-EXPRESSION PATTERNS; NEOADJUVANT TREATMENT; PREDICTIVE-VALUE; HER2; STATUS; PHASE-III; PROGESTERONE-RECEPTOR; C-ERBB-2; EXPRESSION; PROTEIN EXPRESSION; ESTROGEN-RECEPTOR;
D O I：
10.1586/17512433.2014.945429
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Historically, the selection of the most effective adjuvant regimen for breast cancer patients was based on tumor size and nodal status but this approach took into account the stage only, without considering that the biology of the tumor matters as well, as breast cancer is a heterogeneous disease at the molecular level. In the present manuscript we will attempt to address the issue of selecting the most appropriate cytotoxic agents for adjuvant programs in the clinically and biologically distinct subgroups of endocrine responsive ( luminal A and luminal B), HER2 positive and triple negative breast cancer patients.
引用
收藏
页码：605 / 611
页数：7
相关论文
共 76 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
    Aebi, S.
    Sun, Z.
    Braun, D.
    Price, K. N.
    Castiglione-Gertsch, M.
    Rabaglio, M.
    Gelber, R. D.
    Crivellari, D.
    Lindtner, J.
    Snyder, R.
    Karlsson, P.
    Simoncini, E.
    Gusterson, B. A.
    Viale, G.
    Regan, M. M.
    Coates, A. S.
    Goldhirsch, A.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (09) : 1981 - 1987
  • [3] A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
    Alba, E.
    Chacon, J. I.
    Lluch, A.
    Anton, A.
    Estevez, L.
    Cirauqui, B.
    Carrasco, E.
    Calvo, L.
    Segui, M. A.
    Ribelles, N.
    Alvarez, R.
    Sanchez-Munoz, A.
    Sanchez, R.
    Lopez Garcia-Asenjo, J. A.
    Rodriguez-Martin, C.
    Escudero, M. J.
    Albanell, J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (02) : 487 - 493
  • [4] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
    Albain, K.
    Anderson, S.
    Arriagada, R.
    Barlow, W.
    Bergh, J.
    Bliss, J.
    Buyse, M.
    Cameron, D.
    Carrasco, E.
    Clarke, M.
    Correa, C.
    Coates, A.
    Collins, R.
    Costantino, J.
    Cutter, D.
    Cuzick, J.
    Darby, S.
    Davidson, N.
    Davies, C.
    Davies, K.
    Delmestri, A.
    Di Leo, A.
    Dowsett, M.
    Elphinstone, P.
    Evans, V.
    Ewertz, M.
    Gelber, R.
    Gettins, L.
    Geyer, C.
    Goldhirsch, A.
    Godwin, J.
    Gray, R.
    Gregory, C.
    Hayes, D.
    Hill, C.
    Ingle, J.
    Jakesz, R.
    James, S.
    Kaufmann, M.
    Kerr, A.
    MacKinnon, E.
    McGale, P.
    McHugh, T.
    Norton, L.
    Ohashi, Y.
    Paik, S.
    Pan, H. C.
    Perez, E.
    Peto, R.
    Piccart, M.
    [J]. LANCET, 2012, 379 (9814) : 432 - 444
  • [5] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
    Albain, Kathy S.
    Barlow, William E.
    Shak, Steven
    Hortobagyi, Gabriel N.
    Livingston, Robert B.
    Yeh, I-Tien
    Ravdin, Peter
    Bugarini, Roberto
    Boehner, Frederick L.
    Davidson, Nancy E.
    Sledge, George W.
    Winer, Eric P.
    Hudis, Clifford
    Ingle, James N.
    Perez, Edith A.
    Pritchard, Kathleen I.
    Shepherd, Lois
    Gralow, Julie R.
    Yoshizawa, Carl
    Allred, D. Craig
    Osborne, C. Kent
    Hayes, Daniel F.
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 55 - 65
  • [6] Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
    Bartlett, John M. S.
    Munro, Alison F.
    Dunn, Janet A.
    McConkey, Christopher
    Jordan, Sarah
    Twelves, Chris J.
    Cameron, David A.
    Thomas, Jeremy
    Campbell, Fiona M.
    Rea, Daniel W.
    Provenzano, Elena
    Caldas, Carlos
    Pharaoh, Paul
    Hiller, Louise
    Earl, Helena
    Poole, Christopher J.
    [J]. LANCET ONCOLOGY, 2010, 11 (03) : 266 - 274
  • [7] Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
    Blows, Fiona M.
    Driver, Kristy E.
    Schmidt, Marjanka K.
    Broeks, Annegien
    van Leeuwen, Flora E.
    Wesseling, Jelle
    Cheang, Maggie C.
    Gelmon, Karen
    Nielsen, Torsten O.
    Blomqvist, Carl
    Heikkila, Paivi
    Heikkinen, Tuomas
    Nevanlinna, Heli
    Akslen, Lars A.
    Begin, Louis R.
    Foulkes, William D.
    Couch, Fergus J.
    Wang, Xianshu
    Cafourek, Vicky
    Olson, Janet E.
    Baglietto, Laura
    Giles, Graham G.
    Severi, Gianluca
    McLean, Catriona A.
    Southey, Melissa C.
    Rakha, Emad
    Green, Andrew R.
    Ellis, Ian O.
    Sherman, Mark E.
    Lissowska, Jolanta
    Anderson, William F.
    Cox, Angela
    Cross, Simon S.
    Reed, Malcolm W. R.
    Provenzano, Elena
    Dawson, Sarah-Jane
    Dunning, Alison M.
    Humphreys, Manjeet
    Easton, Douglas F.
    Garcia-Closas, Montserrat
    Caldas, Carlos
    Pharoah, Paul D.
    Huntsman, David
    [J]. PLOS MEDICINE, 2010, 7 (05)
  • [8] TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
    Bonnefoi, Herve
    Piccart, Martine
    Bogaerts, Jan
    Mauriac, Louis
    Fumoleau, Pierre
    Brain, Etienne
    Petit, Thierry
    Rouanet, Philippe
    Jassem, Jacek
    Blot, Emmanuel
    Zaman, Khalil
    Cufer, Tanja
    Lortholary, Alain
    Lidbrink, Elisabet
    Andre, Sylvie
    Litiere, Saskia
    Dal Lago, Lissandra
    Becette, Veronique
    Cameron, David A.
    Bergh, Jonas
    Iggo, Richard
    [J]. LANCET ONCOLOGY, 2011, 12 (06) : 527 - 539
  • [9] ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
    Brase, Jan C.
    Schmidt, Marcus
    Fischbach, Thomas
    Sueltmann, Holger
    Bojar, Hans
    Koelbl, Heinz
    Hellwig, Birte
    Rahnenfuehrer, Joerg
    Hengstler, Jan G.
    Gehrmann, Mathias C.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (08) : 2391 - 2401
  • [10] Clinical application of the 70-gene profile: The MINDACT trial
    Cardoso, Fatima
    Van't Veer, Laura
    Rutgers, Emiel
    Loi, Sherene
    Mook, Stella
    Piccart-Gebhart, Martine J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) : 729 - 735
12345678